Abstract
ObjectivesInterleukin-17 (IL-17) contributes to the pathogenesis of psoriasis. Secukinumab, ixekizumab, and brodalumab are monoclonal antibodies anti-IL-17 antibodies, approved for the treatment of moderate/severe plaque psoriasis.The aim of the study was...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have